{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:29:56Z","timestamp":1785392996600,"version":"3.55.0"},"reference-count":37,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"unspecified","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["215490\/Z\/19\/Z"],"award-info":[{"award-number":["215490\/Z\/19\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"accepted":{"date-parts":[[2025,10,8]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Invasive non-typhoidal\n                      <jats:italic>Salmonella<\/jats:italic>\n                      (iNTS) disease is a global health concern, particularly for sub-Saharan Africa. Despite high case fatality risks, there is no vaccine available against the disease. An obstacle to vaccine development is a lack of data on the economic burden of iNTS disease in many parts of the world. The main aim of the current study is to estimate the economic burden of iNTS disease in 123 countries.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Several multivariate regression models were parameterised with the data obtained from an existing systematic literature review on the economic burden of iNTS disease and all forms of NTS disease. Various model diagnostics were performed to validate the statistical significance of each model outcome, and the most suitable model was selected to predict costs in countries where no data points were available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A generalised linear model with gamma distribution with log link was chosen based on model diagnostics. While the average economic burden per iNTS disease episode ranged from US$341 in Africa to US$2194 in Europe, the total economic burden of iNTS disease was the highest in Africa due to the high burden of the disease in the region.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The current study indicates that the economic burden of iNTS disease is substantial. Given the scarcity of field-based iNTS disease economic burden estimates, cost extrapolation through an econometric framework can be helpful for understanding the associated cost implications in a resource-limited setting and for informing the cost-effectiveness of public health interventions including future vaccination strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgh-2025-019370","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T19:10:11Z","timestamp":1762629011000},"page":"e019370","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Estimating the economic burden of invasive non-typhoidal\n                    <i>Salmonella<\/i>\n                    infections in low- and middle-income countries"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1038-8948","authenticated-orcid":false,"given":"Jung-Seok","family":"Lee","sequence":"first","affiliation":[{"name":"Policy and Economic Research, International Vaccine Institute, Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongha","family":"Hwang","sequence":"additional","affiliation":[{"name":"Policy and Economic Research, International Vaccine Institute, Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calman Alexander","family":"MacLennan","sequence":"additional","affiliation":[{"name":"Enteric and Diarrheal Diseases, Bill and Melinda Gates Foundation, Seattle, Washington, USA"},{"name":"Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jit","sequence":"additional","affiliation":[{"name":"Department of Global and Environmental Health, New York University, New York, New York, USA"},{"name":"Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6462-5101","authenticated-orcid":false,"given":"Jean-Louis","family":"Excler","sequence":"additional","affiliation":[{"name":"Business Development, International Vaccine Institute, Seoul, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome H","family":"Kim","sequence":"additional","affiliation":[{"name":"International Vaccine Institute, Gwanak-gu, Korea (the Republic of)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,8]]},"reference":[{"key":"2025120102301516000_10.11.e019370.1","doi-asserted-by":"crossref","unstructured":"Gilchrist JJ , MacLennan CA . Invasive Nontyphoidal Salmonella Disease in Africa. EcoSal Plus 2019;8. doi:10.1128\/ecosalplus.ESP-0007-2018","DOI":"10.1128\/ecosalplus.esp-0007-2018"},{"key":"2025120102301516000_10.11.e019370.2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.7.2465-2467.2000"},{"key":"2025120102301516000_10.11.e019370.3","unstructured":"Grimont P . Antigenic formulae of the Salmonella serovars. WHO Collaborating Centre for Reference and Research on Salmonella 2007."},{"key":"2025120102301516000_10.11.e019370.4","unstructured":"(IHME) IfHMaE . Invasive non-typhoidal salmonella (iNTS) - level 3 cause online: institute for health metrics and evalution (IHME). 2024. Available: https:\/\/www.healthdata.org\/research-analysis\/diseases-injuries-risks\/factsheets\/2021-invasive-non-typhoidal-salmonella-ints [Accessed 20 Jun 2024]."},{"key":"2025120102301516000_10.11.e019370.5","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.vaccine.2024.04.045","article-title":"Vaccine value profile for invasive non-typhoidal Salmonella disease","volume":"42","author":"Martin","year":"2024","journal-title":"Vaccine (Auckl)"},{"key":"2025120102301516000_10.11.e019370.6","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad041"},{"key":"2025120102301516000_10.11.e019370.7","doi-asserted-by":"crossref","first-page":"127515","DOI":"10.1016\/j.vaccine.2025.127515","article-title":"Non-typhoidal Salmonella combination vaccines: clinical development plan and regulatory considerations","volume":"62","author":"Excler","year":"2025","journal-title":"Vaccine (Auckl)"},{"key":"2025120102301516000_10.11.e019370.8","doi-asserted-by":"crossref","first-page":"127008","DOI":"10.1016\/j.vaccine.2025.127008","article-title":"Landscape analysis of invasive non-typhoidal salmonella (iNTS) disease and iNTS vaccine use case and demand: Report of a WHO expert consultation","volume":"55","author":"Emary","year":"2025","journal-title":"Vaccine (Auckl)"},{"key":"2025120102301516000_10.11.e019370.9","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3390\/vaccines12070758","article-title":"The Economic Burden of Non-Typhoidal Salmonella and Invasive Non-Typhoidal Salmonella Infection: A Systematic Literature Review","volume":"12","author":"Kim","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"2025120102301516000_10.11.e019370.10","unstructured":"World bank . In: World Development Indicators. World Bank Group, 2021."},{"key":"2025120102301516000_10.11.e019370.11","doi-asserted-by":"crossref","first-page":"A240","DOI":"10.1016\/j.vaccine.2014.11.061","article-title":"Estimating costs of care for meningitis infections in low- and middle-income countries","volume":"33 Suppl 1","author":"Portnoy","year":"2015","journal-title":"Vaccine (Auckl)"},{"key":"2025120102301516000_10.11.e019370.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00146-8"},{"key":"2025120102301516000_10.11.e019370.13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002055","article-title":"Economic and disease burden of dengue in Southeast Asia","volume":"7","author":"Shepard","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"2025120102301516000_10.11.e019370.14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1478-7547-6-22","article-title":"Capacity utilization and the cost of primary care visits: implications for the costs of scaling up health interventions","volume":"6","author":"Adam","year":"2008","journal-title":"Cost Eff Resour Alloc"},{"key":"2025120102301516000_10.11.e019370.15","doi-asserted-by":"publisher","DOI":"10.1186\/1478-7547-1-3"},{"key":"2025120102301516000_10.11.e019370.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2753.2006.00711.x"},{"key":"2025120102301516000_10.11.e019370.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-6296(98)00025-3"},{"key":"2025120102301516000_10.11.e019370.18","doi-asserted-by":"publisher","DOI":"10.2307\/2288126"},{"key":"2025120102301516000_10.11.e019370.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-6296(01)00086-8"},{"key":"2025120102301516000_10.11.e019370.20","unstructured":"Chatterjee S , Hadi AS . Regression Analysis by Example. John Wiley & Sons, 2015."},{"key":"2025120102301516000_10.11.e019370.21","unstructured":"World Bank . World bank country and lending groups: the world bank. 2024. Available: https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/9065192024"},{"key":"2025120102301516000_10.11.e019370.22","unstructured":"Global burden of disease collaborative network . In: Global Burden of Disease 2021 (GBD 2021): Institute for Health Metrics and Evaluation (IHME). 2021."},{"key":"2025120102301516000_10.11.e019370.23","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-019-2995-4","article-title":"The economic burden of malaria on households and the health system in a high transmission district of Mozambique","volume":"18","author":"Alonso","year":"2019","journal-title":"Malar J"},{"key":"2025120102301516000_10.11.e019370.24","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-020-08595-8","article-title":"Cost of illness for childhood diarrhea in low- and middle-income countries: a systematic review of evidence and modelled estimates","volume":"20","author":"Baral","year":"2020","journal-title":"BMC Public Health"},{"key":"2025120102301516000_10.11.e019370.25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006037","article-title":"A multi-country study of the economic burden of dengue fever: Vietnam, Thailand, and Colombia","volume":"11","author":"Lee","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"2025120102301516000_10.11.e019370.26","unstructured":"World Bank . GDP per capita (current US$): world development indicators. 2024."},{"key":"2025120102301516000_10.11.e019370.27","unstructured":"World Bank . Population density (people per km2 of land area): world development indicators. 2022."},{"key":"2025120102301516000_10.11.e019370.28","unstructured":"World Bank . Urban population (% of total population): world development indicators. 2024."},{"key":"2025120102301516000_10.11.e019370.29","unstructured":"World Bank . Mortality rate, under-5 (per 1,000 live births): world development indicators. 2023."},{"key":"2025120102301516000_10.11.e019370.30","unstructured":"World Bank . Hospital beds. 2021."},{"key":"2025120102301516000_10.11.e019370.31","unstructured":"World Bank . Physicians (per 1,000 people): world development indicators. 2022."},{"key":"2025120102301516000_10.11.e019370.32","unstructured":"World Health Organization . WHO-choice estimates of cost for inpatient and outpatient health service delivery. 2021."},{"key":"2025120102301516000_10.11.e019370.33","unstructured":"World Bank . Life expectancy at birth, total (years): world development indicators. 2023."},{"key":"2025120102301516000_10.11.e019370.34","unstructured":"World Bank . Current health expenditure per capita (current US$): world development indicators. 2023."},{"key":"2025120102301516000_10.11.e019370.35","unstructured":"World Bank . Domestic general government health expenditure (% of general government expenditure): world development indicators. 2023."},{"key":"2025120102301516000_10.11.e019370.36","unstructured":"World Health Organization . Countries by who region."},{"key":"2025120102301516000_10.11.e019370.37","doi-asserted-by":"crossref","unstructured":"Anderson D , Burnham K . Model Selection and Multi-Model Inference. 63. Second NY: Springer-Verlag, 2004.","DOI":"10.1007\/b97636"}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2025-019370","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T10:31:09Z","timestamp":1764585069000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2025-019370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,8]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/bmjgh-2025-019370"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2025-019370","relation":{},"ISSN":["2059-7908"],"issn-type":[{"value":"2059-7908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}